Neuron23, Inc. develops and manufactures medicines for genetic disorders using advanced artificial intelligence technology and genetics. Founded in 2018 and headquartered in South San Francisco, California, with an additional office in Munich, Germany, the company focuses on creating therapeutics for neurological diseases, including Parkinson's and Alzheimer's, as well as immunological disorders. By leveraging recent advancements in human genetics alongside its AI-enabled drug discovery and biomarker platforms, Neuron23 aims to provide innovative treatments for patients suffering from these debilitating conditions, enhancing their quality of life through targeted and effective therapies.
Numab Therapeutics AG is a biotechnology company based in Wädenswil, Switzerland, founded in 2011. The company specializes in developing antibody-based therapeutics aimed at treating severe diseases, including cancer and chronic inflammation. Numab utilizes a unique plug-and-play platform that enhances the predictability of the drug discovery process, allowing for the efficient creation of multispecific biotherapeutics. Its research pipeline encompasses various therapeutic areas, including inflammatory bowel disease, immuno-oncology, autoimmunity, and inflammation.
Neuron23, Inc. develops and manufactures medicines for genetic disorders using advanced artificial intelligence technology and genetics. Founded in 2018 and headquartered in South San Francisco, California, with an additional office in Munich, Germany, the company focuses on creating therapeutics for neurological diseases, including Parkinson's and Alzheimer's, as well as immunological disorders. By leveraging recent advancements in human genetics alongside its AI-enabled drug discovery and biomarker platforms, Neuron23 aims to provide innovative treatments for patients suffering from these debilitating conditions, enhancing their quality of life through targeted and effective therapies.
Monte Rosa Therapeutics is a biotechnology company based in Basel, Switzerland, that specializes in developing innovative cancer therapeutics through the modulation of protein degradation pathways. The company focuses on molecular glue degraders (MGDs), a class of small molecule drugs that utilize the body's natural mechanisms for protein degradation to selectively target and degrade proteins relevant to cancer treatment. Monte Rosa employs its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, to identify and develop target proteins for degradation. With a library of over 50,000 MGD molecules, its leading product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing potential for treating MYC-driven tumors. The company is committed to advancing its pipeline of novel therapeutics to address unmet medical needs in oncology.
ITeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics for cancer treatment. Founded in 2011 and headquartered in Gosselies, Belgium, with operational ties to Cambridge, Massachusetts, the company leverages its expertise in tumor immunology to create small molecule immunomodulators. Its product pipeline includes EOS-850, an antagonist of the adenosine A2a receptor, currently in an open-label Phase 1/2a clinical trial for adult patients, and EOS-448, which targets the TIGIT receptor and is also in a Phase 1/2a clinical trial. ITeos aims to enhance the effectiveness of cancer therapies by targeting resistance mechanisms within the tumor microenvironment, thereby improving the clinical outcomes of existing treatment modalities and newer immunotherapies.
Forbius (Formation Biologics) is a clinical-stage company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases. The company is developing agents targeting the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways, enabling doctors to have highly active inhibitors of validated pathways that have a differentiated mechanism of action. Forbius’ medicines are designed to radically transform patients’ lives. Their strength is utilizing their knowledge of biology and diverse protein engineering technologies to design superior inhibitors of validated biological pathways. Forbius was founded in 2011 as a management-led spin-out from YM BioSciences, prior to YM's acquisition by Gilead.
Sphingotec GmbH, founded in 2002 and located in Brandenburg, Germany, specializes in the development of innovative biomarkers aimed at the diagnosis, prediction, and monitoring of acute medical conditions. Their focus includes critical areas such as acute heart failure, acute kidney injury, and circulatory shock, providing essential tools for healthcare professionals in managing these serious health issues. The company’s advancements in biomarker technology contribute significantly to improving patient outcomes in acute medical scenarios.
ITeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics for cancer treatment. Founded in 2011 and headquartered in Gosselies, Belgium, with operational ties to Cambridge, Massachusetts, the company leverages its expertise in tumor immunology to create small molecule immunomodulators. Its product pipeline includes EOS-850, an antagonist of the adenosine A2a receptor, currently in an open-label Phase 1/2a clinical trial for adult patients, and EOS-448, which targets the TIGIT receptor and is also in a Phase 1/2a clinical trial. ITeos aims to enhance the effectiveness of cancer therapies by targeting resistance mechanisms within the tumor microenvironment, thereby improving the clinical outcomes of existing treatment modalities and newer immunotherapies.
Iconic Therapeutics, Inc. operates as a biopharmaceutical company that translates tissue factor biology in angiogenesis, inflammation, and metastasis to develop new therapeutics for retinal disease and cancer. Its products include ICON-1, a fusion protein designed to address the basis of vision loss in age-related macular degeneration. Iconic Therapeutics, Inc. was incorporated in 2002 and is based in South San Francisco, California.
Private Equity Round in 2018
Gynesonics, Inc. is a healthcare company specializing in the development of minimally invasive solutions for symptomatic uterine fibroids in women. The company offers the Sonata System, which utilizes sonography-guided transcervical fibroid ablation to treat these conditions under intrauterine sonography guidance. Founded in 2005, Gynesonics is headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands. The company serves customers worldwide, focusing on providing advanced, incision-free treatment options for uterine conditions.
Hookipa Pharma is a clinical-stage biopharmaceutical company focused on developing immune-therapeutics for infectious diseases and cancers using its proprietary arenavirus vector platforms. The company operates two main platforms: Vaxwave, aimed at creating prophylactic vaccines, and TheraT, which focuses on immuno-oncology therapies. Its key product candidates include HB-101, a vaccine for cytomegalovirus currently in a Phase II clinical trial for kidney transplant patients, and HB-201 and HB-202, which are in preclinical studies for treating human papillomavirus-positive cancers. Additionally, Hookipa is collaborating with Gilead Sciences to develop therapies for chronic Hepatitis B and HIV infections. Founded in 2011 and based in New York, Hookipa Pharma aims to leverage its innovative technologies to elicit robust immune responses, addressing limitations found in conventional vaccine and therapeutic approaches.
ConnectRN operates an online platform that connects credentialed nurses with healthcare institutions seeking to fill open shifts. The platform features tools that streamline communication between nurses and nurse managers, ensuring that available shifts are promptly filled. By utilizing a mobile alert system, ConnectRN facilitates real-time notifications, enabling healthcare providers to efficiently manage staffing needs and reduce reliance on overtime and agency staff. Founded in 2014 and based in Newton, Massachusetts, ConnectRN aims to provide nurses with greater control over their schedules while helping healthcare facilities address staffing challenges effectively.
Gynesonics, Inc. is a healthcare company specializing in the development of minimally invasive solutions for symptomatic uterine fibroids in women. The company offers the Sonata System, which utilizes sonography-guided transcervical fibroid ablation to treat these conditions under intrauterine sonography guidance. Founded in 2005, Gynesonics is headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands. The company serves customers worldwide, focusing on providing advanced, incision-free treatment options for uterine conditions.
i-Optics B.V. is a medical device company based in The Hague, Netherlands, specializing in the development and distribution of optical devices for eye diagnosis. Founded in 2003, the company offers innovative solutions such as Cassini, a corneal shape analyzer that utilizes color LED technology to measure the true axis and magnitude of corneal astigmatism, which is crucial for premium intraocular lens (IOL) planning. Additionally, i-Optics provides EasyScan, a retinal imaging system that employs scanning laser ophthalmoscopy (SLO) technology to diagnose various retinal diseases, including diabetic retinopathy, age-related macular degeneration, and glaucoma, without the need for pupil dilation. Through its advanced, user-friendly products, i-Optics aims to enhance the quality of eye care for healthcare providers and their patients worldwide.
Symbiomix Therapeutics, LLC is a biopharmaceutical company focused on developing innovative treatments for serious women's health infections, particularly bacterial vaginosis (BV). Founded in 2012, the company is based in Newark, New Jersey, with additional offices in Baltimore, Maryland, and Hamden, Connecticut. Its lead product, Solosec (secnidazole), is a novel 5-nitroimidazole antibiotic designed for a one-time oral treatment of bacterial vaginosis, addressing a significant unmet need in women's healthcare. Symbiomix operates as a subsidiary of Lupin Inc. and is supported by prominent healthcare venture capital firms. The company aims to provide effective therapeutic options for gynecologic infections that have been historically overlooked.
APR Applied Pharma Research s.a. is a pharmaceutical company based in Balerna, Switzerland, specializing in the identification, development, manufacturing, and licensing of healthcare products across various therapeutic areas. Founded in 1990, the company focuses on creating oral and topical formulations, including prescription and over-the-counter pharmaceuticals, nutraceuticals, dermocosmetics, and medical devices. Its innovative drug delivery systems cater to a wide range of applications, addressing conditions such as cancer supportive care, CNS disorders, dermatology, gynecology, and pain management, among others. APR is particularly dedicated to meeting the needs of patients with rare diseases and aims to enhance healthcare outcomes through patient-centric solutions. The company has a strategic focus on markets in Europe and the United States, as well as emerging markets like China, Russia, and Latin America, ensuring a broad reach for its products and services.
Allena Pharmaceuticals is developing and commercializing non-systemic protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrology and urologic conditions. Its proprietary technological approach enables the design, formulation, and delivery of non-absorbed and stable enzymes orally and in sufficient doses for activity in the GI tract.
It was founded in 2011 and headquartered in Newton, Massachusetts.
Curetis AG focuses on multiparameter testing of many analytes in a single run, providing broad panels of combined pathogen and resistance gene detection for a wide range of diseases.
Curetis integrates today´s molecular diagnostics laboratory into one instrument for the detection of severe bacterial infections as a first target application. However, the universal platform will also allow the future expansion into other clinical applications with additional market opportunities beyond infectious diseases.
Gynesonics, Inc. is a healthcare company specializing in the development of minimally invasive solutions for symptomatic uterine fibroids in women. The company offers the Sonata System, which utilizes sonography-guided transcervical fibroid ablation to treat these conditions under intrauterine sonography guidance. Founded in 2005, Gynesonics is headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands. The company serves customers worldwide, focusing on providing advanced, incision-free treatment options for uterine conditions.
Gynesonics, Inc. is a healthcare company specializing in the development of minimally invasive solutions for symptomatic uterine fibroids in women. The company offers the Sonata System, which utilizes sonography-guided transcervical fibroid ablation to treat these conditions under intrauterine sonography guidance. Founded in 2005, Gynesonics is headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands. The company serves customers worldwide, focusing on providing advanced, incision-free treatment options for uterine conditions.
Odyssey Thera, Inc. identifies and develops therapies for the treatment of cancer. The company develops technologies that are focused on deciphering biologically-relevant pathways in living human cells to improve the process of target and drug discovery and to advance methods for environmental chemical toxicity assessment. Its product pipeline includes small molecule inhibitors that block key signaling nodes in human cancer cells. The company was formerly known as Odyssey Pharmaceuticals, Inc. Odyssey Thera, Inc. was incorporated in 2002 and is based in San Ramon, California.
Private Equity Round in 2013
Reha Technology AG is a Swiss company based in Olten that specializes in the design, manufacture, and global distribution of robotic-assisted systems for neurorehabilitation. Established in 2012, the company focuses on developing advanced devices, such as the G-EO System, which aids in gait rehabilitation for individuals with neurological movement disorders. The primary goal of Reha Technology AG is to enhance patients' capabilities in personal self-care and daily activities by rebuilding their functional abilities and skills for greater independence. The company has created an extensive distributor network worldwide and has established direct operations in the United States and India, with plans for future expansion into Latin America.
Nabriva Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative anti-infective agents to address serious bacterial infections. The company's lead product, lefamulin, is a semi-synthetic pleuromutilin antibiotic designed to treat community-acquired bacterial pneumonia and acute bacterial skin infections. It is currently undergoing clinical trials for additional applications, including pediatric infections, sexually transmitted infections, osteomyelitis, and prosthetic joint infections. Nabriva is also advancing CONTEPO, an epoxide antibiotic aimed at treating complicated urinary tract infections, and it is in clinical trials for peri-operative prophylaxis. Founded in 2005 and headquartered in Dublin, Ireland, Nabriva Therapeutics has evolved from its earlier identity as a research institute focused on antibiotic development.
Sloning BioTechnology has developed a unique and patented technology platform to build DNA molecules with exceptional features regarding sequence limitations, reliability and production cost on an industrial scale robotic system the Slonomics technology platform.
Gemin X Pharmaceuticals is dedicated to the discovery, development and commercialization of novel, targeted cancer therapeutics to improve the lives of patients. Gemin X's research on the Bcl-2 cell death regulation pathway has led to the discovery of GX15-070 (obatoclax), a novel small molecule that selectively reinitiates programmed cell death, or apoptosis, and may also be effective in inducing cancer cell self-digestion, or autophagy. Obatoclax has shown promising activity in both preclinical and early human clinical studies and is currently in Phase 2 clinical trials as both a single agent and combination therapy. Obatoclax has patent protection through 2025.
Asthmatx, Inc., a medical device company, focuses on developing and commercializing a therapeutic treatment for asthma in the United States. The company has developed a technology that is designed to deliver controlled thermal energy to the airways of adult patients to reduce the mass of airway smooth muscle in a procedure called Bronchial Thermoplasty. Asthmatx offers an interventional medical device, called the Alair System, for the bronchoscopic treatment of patients with moderate to severe asthma. Asthmatx was founded in 2003 and is headquartered in Mountain View, California. As of October 26, 2010, Asthmatx operates as a wholly-owned subsidiary of [Boston Scientific](/organization/boston-scientific).
Newron Pharmaceuticals S.p.A. is a clinical stage biopharmaceutical company dedicated to the research, development, manufacture, and distribution of therapies for central and peripheral nervous system disorders, as well as pain management. Headquartered in Bresso, Italy, and with a subsidiary in Morristown, NJ, USA, the company is known for its commercial product Xadago (safinamide), which is approved for the treatment of Parkinson’s disease in multiple regions, including the European Union and the United States. Newron's pipeline includes promising candidates such as Sarizotan for Rett syndrome, Evenamide as a potential first add-on therapy for schizophrenia, and Ralfinamide targeting specific rare pain conditions. Established in 1999, Newron Pharmaceuticals continues to advance its innovative therapies aimed at improving the lives of patients with challenging medical conditions.
Private Equity Round in 2005
Anadys Pharmaceuticals is a biopharmaceutical company based in San Diego, California, focused on developing treatments for chronic hepatitis C viral infections. The company is primarily working on ANA598, a direct-acting antiviral agent designed to inhibit the hepatitis C virus. Additionally, Anadys is investigating ANA773, an oral small-molecule inducer of endogenous interferons that activates the Toll-like receptor 7 pathway. Founded in 1992, Anadys Pharmaceuticals operates as a subsidiary of Hoffmann-La Roche Inc.
AGY Therapeutics has one focus: the discovery, development and commercialization of breakthrough treatments for diseases of the central nervous system AGY has a pipeline of novel CNS therapeutic programs in the clinic and in preclinical development to meet major unmet medical needs. AGY built its pipeline using its unique, proprietary platform for functional gene discovery and mapping out specific pathways underlying central nervous system diseases. By harnessing these capabilities, AGY identified potential target proteins that can be modulated to block the progression of the disease process. This is paving the way for novel CNS therapeutics and future growth for AGY.
Aspreva Pharmaceuticals Corp is an emerging pharmaceutical company headquartered in Victoria, British Columbia focused on identifying, developing and commercializing new indications for approved drugs and drug candidates for underserved patient populations. Their strategy, which they call “indication partnering”, is to collaborate with pharmaceutical and biopharmaceutical companies to pursue new indication approvals which lie beyond their strategic focus.
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapies for cancer and other proliferative diseases. Founded in 1996 by Professor Sir David Lane, a pioneer in tumor suppressor biology, the company specializes in targeting cell cycle control mechanisms. Its oncology programs include CYC065, a cyclin-dependent kinase inhibitor currently in Phase I trials for solid tumors and chronic lymphocytic leukemia, and CYC140, a polo-like kinase inhibitor also in Phase I trials for advanced leukemias. Additionally, Cyclacel is advancing sapacitabine, an oral nucleoside analogue, through multiple studies, including a Phase III trial for acute myeloid leukemia and combination studies with other agents for patients with BRCA mutations. The company collaborates with the University of Texas MD Anderson Cancer Center to evaluate the safety and efficacy of its drugs in hematological malignancies, and has a partnership with ManRos Therapeutics for the development of oral seliciclib capsules for cystic fibrosis. Cyclacel is headquartered in Berkeley Heights, New Jersey.
Sloning BioTechnology has developed a unique and patented technology platform to build DNA molecules with exceptional features regarding sequence limitations, reliability and production cost on an industrial scale robotic system the Slonomics technology platform.
Agensys is a biotechnology company focused on the research and development of therapeutic human monoclonal antibodies and antibody-drug conjugates specifically for cancer treatment. The company offers products aimed at addressing various tumors, including those associated with prostate, pancreatic, bladder, kidney, lung, and colon cancers. Founded in 1997 and based in Santa Monica, California, Agensys operates as a subsidiary of Astellas Pharma US, Inc. It is dedicated to providing innovative therapeutic solutions to improve patient outcomes in oncology.
Private Equity Round in 2001
Syrrx Inc focuses on drug targets that have been validated in human clinical trials and directs its efforts toward therapeutics to treat metabolic diseases, cancer, and inflammation. Syrrx exploits its competitive advantage in high-throughput structural biology to be the first organization to determine the three dimensional structure of known drug targets. Syrrx then uses these structures to drive iterative, structure-based drug design programs to efficiently generate potential drug candidates. Syrrx has an ongoing partnership for the development and commercialization of Syrrx-designed human dipeptidyl peptidase IV (DPP IV) inhibitors as drug products for the treatment of type 2 diabetes and other major human diseases. Syrrx also has a strategic alliance for the discovery and early development of inhibitors targeting human HDACs and HSD1.